SUNNYVALE (dpa-AFX) - Intuitive surgical (ISRG) announced the FDA cleared a
labeling revision for da Vinci X and Xi specific to radical prostatectomy. The
clearance was based on real-world evidence collected from 2007 to 2014 that
showed overall five- to 10-year survival following robotic-assisted radical
prostatectomy is similar to non-robotic radical prostatectomy.

The company said the labeling change applies specifically to the Precaution for
Representative Uses statement for the da Vinci X and Xi systems. The previous
precaution statement noted that the FDA did not review evaluation of outcomes
related to the treatment of cancer.

Intuitive Chief Medical Officer Myriam Curet, said: 'This is a significant step
because it confirms non-inferiority for overall survival at 10 years for
patients undergoing radical prostatectomy with the da Vinci surgical system.'

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX